Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 8, 2007, Pages 942-947

  Nachbaur, David ^a   Schumacher, Petra ^a   Auberger, Jutta ^a   Clausen, Johannes ^a   Kircher, Brigitte ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Activin A; Allogeneic hematopoietic stem cell transplantation; Vascular endothelial growth factor

Indexed keywords

ACICLOVIR; ACTIVIN A; COTRIMOXAZOLE; CYCLOSPORIN A; FLUCONAZOLE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; THYMOCYTE ANTIBODY; VALACICLOVIR; VASCULOTROPIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HIGH RISK PATIENT; HUMAN; HUMAN CELL; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUTROPHIL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REFERENCE VALUE; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ACTIVINS; ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEUTROPHILS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34447340291     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.04.007     Document Type: Article

References (28)

1. Appelbaum F.R. The current status of hematopoietic cell transplantation. Annu Rev Med 54 (2003) 491-512
2. Delve L.D., Schulman H., and McDonald G.B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (venom-occlusive disease). Semin Liver Dis 22 (2002) 27-41
3. Barman S.I. The syndrome of hepatic venom-occlusive disease after marrow transplantation. Blood 85 (1995) 3005-3020
4. Wadleigh M., Ho V., Momtaz P., and Richardson P. Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Curr Opin Hematol 10 (2003) 451-462
5. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
6. Munz B., Hübner G., Tretter Y., Alzheimer C., and Werner S. A novel role of activin in inflammation and repair. J Endocrinol 161 (1999) 187-193
7. Jones K.L., de Kretser D.M., Patella S., and Phillips D.J. Activin A and follistatin in systemic inflammation. Mol Cell Endocrinol 225 (2004) 119-125
8. Nachbaur D., Clausen J., and Kircher B. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants. Eur J Haematol 76 (2006) 414-419
9. O'Donnell P.V., Luznik L., Jones R.J., et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant 8 (2002) 377-386
10. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314 (1986) 729-735
11. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic stem cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-4000
12. Nachbaur D., Eibl B., Kropshofer G., et al. In vivo T cell depletion with low-dose rabbit antithymocyte globulin results in low transplant-related mortality and low relapse incidence following unrelated hematopoietic stem cell transplantation. J Hematother Stem Cell Res 11 (2002) 731-737
13. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18 (1974) 295-301
14. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980) 204-211
15. Marr K., Seidel K., Slavin M., et al. Prolonged fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. Blood 96 (2002) 2055-2061
16. Kaplan E.L., and Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
17. Gooley T.A., Leisenring W., Crowley J., and Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representation of old estimators. Stat Med 18 (1999) 695-706
18. Min C.-K., Kim S.Y., Lee M.J., et al. Vascular endothelial growth factor (VEGF) is associated with a reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantion. Bone Marrow Transplant 38 (2006) 149-156
19. Iguchi A., Kobayashi R., Yoshida M., et al. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation. Bone Marrow Transplant 27 (2001) 1173-1180
20. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
21. Ferrara J.L., and Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 43 (2006) 3-10
22. Gunsilius E., Petzer A., Stockhammer G., et al. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 58 (2000) 169-174
23. Salven P., Orpana A., and Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 5 (1999) 2978-2989
24. Yu J., and Dolter K.E. Production of activin A and its roles in inflammation and hematopoiesis. Cytokines Cell Mol Ther 3 (1997) 169-177
25. Shulman H.M., Gown A.M., and Nugent D.J. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 127 (1987) 549-558
26. Eltumi M., Trivedi P., Hobbs J.R., et al. Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen. Lancet 342 (1993) 518-521
27. Rio B., Bauduer F., Arrago J.P., and Zittoun R. N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Blood 83 (1994) 3036-3040
28. Anscher M.S., Peters W.P., Reisenbichler H., Petros W.P., and Jirtle R.L. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 328 (1993) 1592-1598